JPWO2020030977A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020030977A5 JPWO2020030977A5 JP2021506465A JP2021506465A JPWO2020030977A5 JP WO2020030977 A5 JPWO2020030977 A5 JP WO2020030977A5 JP 2021506465 A JP2021506465 A JP 2021506465A JP 2021506465 A JP2021506465 A JP 2021506465A JP WO2020030977 A5 JPWO2020030977 A5 JP WO2020030977A5
- Authority
- JP
- Japan
- Prior art keywords
- once
- alk
- alk inhibitor
- weeks
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims 23
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 16
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 16
- 238000002649 immunization Methods 0.000 claims 12
- 230000003053 immunization Effects 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 8
- 230000004927 fusion Effects 0.000 claims 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 5
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 claims 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 4
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 4
- 229960001611 alectinib Drugs 0.000 claims 4
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 claims 4
- 229950004272 brigatinib Drugs 0.000 claims 4
- 229960001602 ceritinib Drugs 0.000 claims 4
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims 4
- 229960005061 crizotinib Drugs 0.000 claims 4
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical group O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 4
- 102000045108 human EGFR Human genes 0.000 claims 4
- 229950001290 lorlatinib Drugs 0.000 claims 4
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 230000002074 deregulated effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 238000011452 sequencing regimen Methods 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862715351P | 2018-08-07 | 2018-08-07 | |
| US62/715,351 | 2018-08-07 | ||
| US201862727056P | 2018-09-05 | 2018-09-05 | |
| US62/727,056 | 2018-09-05 | ||
| US201862748772P | 2018-10-22 | 2018-10-22 | |
| US62/748,772 | 2018-10-22 | ||
| US201862760529P | 2018-11-13 | 2018-11-13 | |
| US62/760,529 | 2018-11-13 | ||
| US201962822290P | 2019-03-22 | 2019-03-22 | |
| US62/822,290 | 2019-03-22 | ||
| PCT/IB2019/000905 WO2020030977A2 (en) | 2018-08-07 | 2019-08-07 | Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534094A JP2021534094A (ja) | 2021-12-09 |
| JPWO2020030977A5 true JPWO2020030977A5 (enExample) | 2022-08-12 |
Family
ID=68425157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506465A Pending JP2021534094A (ja) | 2018-08-07 | 2019-08-07 | 未分化リンパ腫キナーゼ阻害剤と組み合わせてｅｇｆ／ｅｇｆｒ経路を抑制するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12257245B2 (enExample) |
| EP (1) | EP3833384A2 (enExample) |
| JP (1) | JP2021534094A (enExample) |
| KR (1) | KR20210041571A (enExample) |
| CN (1) | CN112996534B (enExample) |
| AU (1) | AU2019319109A1 (enExample) |
| BR (1) | BR112021002145A2 (enExample) |
| CA (1) | CA3108236A1 (enExample) |
| IL (1) | IL280632A (enExample) |
| MX (1) | MX2021001398A (enExample) |
| WO (1) | WO2020030977A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112300284B (zh) * | 2020-12-29 | 2021-04-06 | 慈达(广州)生物技术有限公司 | 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒 |
| WO2022256360A1 (en) * | 2021-06-02 | 2022-12-08 | Neuvogen, Inc. | Tumor cell vaccines |
| WO2023059801A1 (en) * | 2021-10-06 | 2023-04-13 | The Regents Of The University Of Colorado, A Body Corporate | Biomarkers for egfr-mediated resistance in oncogene-driven cancers and methods of treating, preventing, and/or ameliorating oncogene-driven cancers |
| KR102685187B1 (ko) | 2021-10-15 | 2024-07-16 | 제이투에이치바이오텍 (주) | Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 |
| CA3236522A1 (en) * | 2021-10-28 | 2023-05-04 | In3Bio Ltd. | Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors |
| TW202339767A (zh) * | 2022-01-18 | 2023-10-16 | 大陸商齊魯製藥有限公司 | 螺環芳基磷氧化物與抗ｅｇｆｒ抗體的聯用藥物組合物及其用途 |
| WO2024017352A1 (zh) * | 2022-07-22 | 2024-01-25 | 四川大学 | 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒 |
| WO2024249331A1 (en) * | 2023-05-26 | 2024-12-05 | The Board Of Regents Of The University Of Texas System | Combined rtk and alk inhibition in rtk driven cancers |
| KR20250120789A (ko) | 2024-02-02 | 2025-08-11 | 제이투에이치바이오텍 (주) | E3 리가제 리간드 화합물, alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPH10147952A (ja) | 1996-11-18 | 1998-06-02 | Komatsu Ltd | ブルドーザのドージング装置 |
| US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| KR20140064971A (ko) * | 2011-09-19 | 2014-05-28 | 제넨테크, 인크. | c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료 |
| MX347772B (es) | 2012-03-06 | 2017-05-12 | Cephalon Inc | Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak. |
| US20150218652A1 (en) * | 2012-08-31 | 2015-08-06 | The Regents Of The Unversity Of Colorado, A Body Corporate | Methods for diagnosis and treatment of cancer |
| US20160017431A1 (en) * | 2014-03-28 | 2016-01-21 | Driver Group | Methods for Predicting EGFR Tyrosine Kinase Inhibitor Efficacy |
| CA2946538A1 (en) * | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| US20160333087A1 (en) * | 2015-05-12 | 2016-11-17 | Bioven 3 Limited | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors |
| EP3303399A1 (en) * | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies |
| KR20180025888A (ko) * | 2015-06-08 | 2018-03-09 | 제넨테크, 인크. | 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법 |
| JP7751357B2 (ja) | 2017-07-18 | 2025-10-08 | イン３バイオ・リミテッド | 合成タンパク質およびその治療学的用途 |
| RU2654695C1 (ru) | 2017-07-28 | 2018-05-22 | Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") | 8-(1-{ 4-{ (5-Хлор-4-{ (2-(диметилфосфорил)фенил)амино} пиримидин-2-ил)амино)-3-метоксифенил} пиперидин-4-ил)-1-метил-1,8-диазаспиро(4.5)декан-2-он и его фармацевтически приемлемые соли в качестве модулятора ALK и EGER, предназначенные для лечения рака |
-
2019
- 2019-08-07 CA CA3108236A patent/CA3108236A1/en active Pending
- 2019-08-07 BR BR112021002145A patent/BR112021002145A2/pt unknown
- 2019-08-07 WO PCT/IB2019/000905 patent/WO2020030977A2/en not_active Ceased
- 2019-08-07 CN CN201980062030.6A patent/CN112996534B/zh active Active
- 2019-08-07 EP EP19797349.8A patent/EP3833384A2/en active Pending
- 2019-08-07 MX MX2021001398A patent/MX2021001398A/es unknown
- 2019-08-07 US US16/534,230 patent/US12257245B2/en active Active
- 2019-08-07 AU AU2019319109A patent/AU2019319109A1/en active Pending
- 2019-08-07 KR KR1020217004498A patent/KR20210041571A/ko active Pending
- 2019-08-07 JP JP2021506465A patent/JP2021534094A/ja active Pending
-
2021
- 2021-02-02 IL IL280632A patent/IL280632A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2282656T3 (es) | Uso del derivado de quinazolina zd6474 combinado con gemcitabina y opscionalmente radiacion ionizante en el tratamiento del cancer. | |
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| JP7579465B2 (ja) | 頭頸部癌の治療のためのｅｇｆｒ阻害剤 | |
| JP2008528486A5 (enExample) | ||
| JP2018109022A5 (enExample) | ||
| WO2019096194A1 (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2011511074A (ja) | 結腸直腸癌を治療するためのピコプラチンおよびセツキシマブの使用 | |
| JP2019517549A5 (enExample) | ||
| WO2020030977A3 (en) | Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors | |
| JPWO2020030977A5 (enExample) | ||
| JPWO2022269525A5 (enExample) | ||
| JP2009544610A5 (enExample) | ||
| CN104812400A (zh) | 使用伏拉塞替的组合治疗 | |
| RU2020134183A (ru) | Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы | |
| CN113840608B (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| US20240216333A1 (en) | Treatment of glioblastoma | |
| TW202528000A (zh) | 人類表皮生長因子第二型受體疫苗組成物以及套組 | |
| TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
| CN118055775A (zh) | 包括hsp90抗原肽的抗癌用疫苗组合物及其用途 | |
| RU2021105387A (ru) | Способы и композиции для подавления пути egf/egfr в комбинации с ингибиторами киназы анапластической лимфомы | |
| US20250381190A1 (en) | Therapeutic combinations of capivasertib and venetoclax | |
| US20250049802A1 (en) | Combination therapies and uses for treating cancer | |
| WO2008135792A1 (en) | Pm00104 compound for use in cancer therapy | |
| JP2025541662A (ja) | カピバセルチブ及びベネトクラクスの治療用組み合わせ | |
| TW202535477A (zh) | 抗ｂ７ｈ３抗體—藥物偶聯物治療癌症的方法 |